Skip to main content
Midas Edge

Avalo Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

AVTX$7.16-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

ExhibitNumberDescription of Exhibit
3.1Certificate of Designation for Avalo Therapeutics, Inc.’s Series C-1 Preferred Stock filed with the Secretary of State of Delaware on June 11, 2026 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 12, 2026).
4.1Form of Pre-funded Warrant issued May 7, 2026 by Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on May 7, 2026).
10.1#Amendment No.2 to Garry Neil Letter Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 12, 2026).
10.2#Amendment No.3 to Christopher Sullivan Letter Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on June 12, 2026).
10.3#Amendment No.1 to Mittie Doyle Employment Agreement (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on June 12, 2026).
10.4#Amendment No.1 to Taylor Boyd Employment Agreement (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on June 12, 2026).
10.5+#Amendment No. 1 to Paul Varki Employment Agreement.
10.6+#Amendment No. 1 to Jennifer Riley Employment Agreement.
10.7#Second Amended and Restated 2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 8, 2026).
21.1+List of Subsidiaries of the Registrant.
31.1+Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2+Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1†Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025; (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the Three and Six Months Ended June 30, 2026 and 2025; (iii) Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2026 and 2025; (iv) Condensed Consolidated Statements of Mezzanine and Stockholders’ Equity (Unaudited) for the Three and Six Months Ended June 30, 2026 and 2025; and (v) Notes to Unaudited Financial Statements.
104Cover Page Interactive Data File, formatted in XBRL (included in Exhibit 101).
  • Filed herewith.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.